Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Laboratory

Center for Studies and Research for the Intensification of Diabetes Treatment


Genopole Campus 3 – Building 5 – 1 rue Pierre Fontaine
91058 EVRY cedex – FRANCE
Téléphone : +33 1 64 96 88 60
Email : dir@ceritd.fr

President : CHARPENTIER Guillaume
Site Web >
CERITD CERITD

#Clinical Research #E-health

  • Type 1 diabetes, Type 2 diabetes
  • Genetics
  • Artificial pancreas
  • Insulin pump
  • Clinical research
  • Telemedicine
  • Innovative technologies
  • Cooperation protocol
  • Therapeutic education
  • Evaluation

Field of Activity


– Ambulatory healthcare center for diabetic patients treated with external insulin pumps.
– Translational clinical research center.

Genetics and prediction of type 2 diabetes:

  • – Establishment of a computerized database (clinical and medical history, social-economic and biological data) and a DNA bank (6,000 patients) under the management of Prof. Froguel’s team in Lille, France.
  • Sponsor of the Descendants program aimed at validating a method for detecting glycemic abnormalities at different ages in the children of people with type 2 diabetes.

Innovative technologies:

  • Sponsor of clinical studies.
  • Founding member of Diabeloop, a French consortium for the development of an artificial pancreas for glycemia control in diabetic patients.
  • Modeling of postprandial glycemia in type 2 diabetes patients.
  • Modeling of glycemia during different levels of physical activity.

Epidemiological cohort monitoring:

  • Prospective monitoring of patients treated by insulin pumps in the southern Greater Paris area.
  • European collaborative study to assess the quality of type 2 diabetes management and its coherence with existing recommendations in eight European countries.

Telemedicine:

  • Development of algorithms to automatically calculate insulin doses; decision-making support and patient coaching via electronic blood glucose journals for type 1 (at the origin of the Diabéo system) and type 2 diabetes patients.
  • Development of a shared information system for health professionals (ePEP software) permitting telemedical monitoring of patients using electronic blood glucose journals.
  • COLLABORATION / CHAIRE

    Numerous collaborations over many projects in the fields of type 2 diabetes genetics and maturity onset diabetes of the young (MODY):
    – development of innovative technologies,
    – scientific, industrial,
    – pharmacological and institutional collaborations,
    – reorganization of care provision.

Share
Genopole’s Laboratories

#Clinical Research


In same field

With the support from
Région île de France